CPT® Code 90683

The CPT® Code 90683 refers to the respiratory syncytial virus (RSV) vaccine, which utilizes mRNA lipid nanoparticles for intramuscular administration. This vaccine is designed to provide active and long-term immunity by introducing a modified version of the RSV to the recipient's immune system. The process involves the immune system recognizing the altered virus, which prompts the production of specific antibodies that can combat the actual virus upon future exposure. RSV is a highly contagious virus that primarily affects infants, young children, and vulnerable populations such as the elderly, immunocompromised individuals, and those with pre-existing health conditions like diabetes, congestive heart failure, asthma, or chronic obstructive pulmonary disease (COPD). Infection with RSV can lead to severe respiratory illnesses, including pneumonia, which may necessitate hospitalization and can be fatal. The mRNA lipid nanoparticle-based vaccine works by expressing a chemically modified form of the RSV prefusion F glycoprotein, which is crucial for the virus's entry into host cells. This genetic material is encapsulated within a protective lipid nanoparticle, ensuring its safe delivery into the host cells. Once inside, the mRNA instructs the cells to produce the antigen protein, triggering an immune response that results in the production of antibodies. This mechanism not only provides a robust immune response but also ensures that the immunity generated is both safe and long-lasting, particularly beneficial for children and adults alike. It is important to note that this code specifically reports the vaccine product itself and does not encompass the administration of the vaccine via intramuscular injection.